SVIBOR - Project code: 3-01-099

MINISTRY OF SCIENCE AND TECHNOLOGY

Strossmayerov trg 4, HR - 10000 ZAGREB
tel.: +385 1 459 44 44, fax: +385 1 459 44 69
E-mail: ured@znanost.hr

SVIBOR - Collecting Data on Projects in Croatia

Project code: 3-01-099

HYPERTHERMIA AND IMMUNOTHERAPY AS A NEW COMBINED THERAPY OF TUMOUR DISEASE

Main researcher: TARADI, MILAN (49133)

Assistants

ANDREIS, IGOR (496)
KOZJEK, LIDIJA (123743)

Type of research: basic
Duration from: 04/30/91. to 12/31/95.

Papers on project (total): 9
Papers on project quoted in Current Contents: 4

Institution name: Medicinski fakultet, Zagreb (108)
Department/Institute: Department of Physiology
Address: Šalata 3, POB 978
City: 10000 - Zagreb, Croatia

Communication: Phone: 385 (0)1 45 66 921

Summary: The effect of immunostimulation and hyperthermia on experimental tumour growth was studied. The combined thermoimunotherapy strongly inhibit tumour growth and the incidence of spontaneous metastasis. The described study suggest that this therapy could be used as an potent anticamcer treatment modality. We have studied the effect of a streptococcal preparation, OK-432 (Picibanil), given alone or in combination with hyperthermia on murine tumour and normal tissue. OK-432 after local administration enhanced the termal response of murine tumor and normal tissue. This enhancement was greater for the tumour than for the normal tissue, resulting in a favourable differential effect between normal and malignant tissue (the average therapeutic gain was 1,33 +-0,19). Further studies were conducted to disclose the mehanism of OK-432 induced thermal enhancement. Although OK-432 showed a slight direct cytotoxic activity against tumour cells in vitro, the in vivo antitumour effect of combined OK-432 and hyperthermia treatmens was greater than the effect expected from in vitro cytotoxicity, indicating the involvement od the host-mediated mechanisms.

Keywords: hyperthermia, immunotherapy, thermoterapy

Research goals: The purpos of this project was to examine the effects of hyperthermia and immunotherapia on tumour growth. The results suggests that combined thermoimmunotherapy could be a potentant anticancer tretment. The streptococal agent, OK-432 (Picibanil) can be employ for immunotherapy and thermotherapz of patient with malignant tumours.

COOPERATION - INSTITUTIONS

Name of institution: Department of Radiation Medicine, University of Kentucky, Lexington, KY, USA
Type of institution: Economical/Production
City: 40536-0084 - Lexington, Kentucky, USA

Other information about the project.


Ministry of Science and Technology	Croatian language	Svibor homepage	Alphabetic list	Sorted on project code	Sorted on institutions	Search	Help

Last update: 10/17/95
Information: svibor@znanost.hr